Clinical trials: PMDD
Premenstrual Syndrome, Premenstrual Dysphoric Disorder
CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life
This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device…
- Conditions
- Premenstrual Syndrome, Premenstrual Dysphoric Disorder, Dysmenorrhea, Endometriosis
- Trial name
- CREST (NCT07679074)
- Testing
- Lutea Transcranial Direct Current Stimulation (tDCS) Device, Samphire Guided Care Program
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Samphire Group, Inc.
Menstruation Disturbances, Premenstrual Syndrome
Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder
The purpose of this study is to determine whether levonorgestrel (LNG)/ethinyl estradiol (EE) is effective in treating the symptoms of severe premenstrual syndrome (PMS).
- Trial name
- NCT00128934
- Testing
- levonorgestrel/ethinyl estradiol
- Where
- 83 sites in United States, Canada
- Volunteers
- 744 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Premenstrual Dysphoric Disorder ( PMDD)
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
The purpose of this study is to evaluate the efficacy and safety of YAZ compared to placebo in the treatment of symptoms related to Premenstrual Dysphoric Disorder (PMDD).
- Trial name
- NCT00824187
- Testing
- EE20/DRSP(YAZ, BAY86-5300)
- Where
- 16 sites in China
- Volunteers
- 187 people
- Sponsor
- Bayer
Premenstrual Syndrome, Menstruation Disturbances
Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder
The purpose of this study is to determine whether Levonorgestrel/Ethinyl Estradiol (LNG/EE) is effective in treating the symptoms of severe Premenstrual Dysphoric Disorder.
- Trial name
- NCT00195559
- Testing
- Levonorgestrel/Ethinyl Estradiol
- Where
- 51 sites in Argentina, Brazil and 10 more
- Volunteers
- 526 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Contraception, Premenstrual Syndrome
Regulatory Post Marketing Surveillance Study on YAZ
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice.
- Conditions
- Contraception, Premenstrual Syndrome, Acne
- Trial name
- NCT00998257
- Testing
- EE20/DRSP (YAZ, BAY86-5300)
- Where
- South Korea
- Volunteers
- 770 people
- Sponsor
- Bayer
Premenstrual Dysphoric Disorder
A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)
The objective of this phase IIb study is to evaluate the effect and safety of Sepranolone (UC1010) on premenstrual symptoms in women with Premenstrual Dysphoric Disorder (PMDD).
- Trial name
- NCT03697265
- Testing
- Sepranolone (UC1010) low dose, Sepranolone (UC1010) high dose
- Where
- 12 sites in Germany, Poland and 2 more
- Volunteers
- 475 people
- Sponsor
- Asarina Pharma
Premenstrual Dysphoric Disorder ( PMDD), PMDD
MLS101 Study in PMDD
The goal of this clinical trial is to learn if MLS101 (psilocybin) is a possible treatment for women with Premenstrual Dysphoric Disorder (PMDD).
- Trial name
- NCT07818720
- Testing
- MLS101 psilocybin
- Volunteers
- 32 people
- Sponsor
- MycoMedica Life Sciences PBC
Premenstrual Dysphoric Disorder
Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
The objective of this study is to evaluate the effectiveness and safety in double-blind, randomized, placebo-controlled clinical trials of self administered PH80 intranasal spray for the acute management of cycle related symptoms…
- Trial name
- PH80-PMD (NCT01217775)
- Testing
- PH80
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Pherin Pharmaceuticals, Inc.
Premenstrual Dysphoric Disorder
A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)
The study is a phase 1/2 study in two parts. In part 1, the primary objective is to assess the pharmacokinetics of UC1010 when administered subcutaneously as a single dose to healthy women.
- Trial name
- NCT01875718
- Testing
- UC1010
- Where
- Sweden
- Volunteers
- 146 people
- Sponsor
- Umecrine Mood AB